• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Successful treatment of an 82-year-old COVID-19 delta variant-infected patient with haemorrhagic stroke and active prostate cancer brain metastasis
Clin Transl Discov. 2022 Mar;2(1):e20. doi: 10.1002/ctd2.20. Epub 2022 Jan 12.NO ABSTRACTPMID:35464128 | PMC:PMC9015616 | DOI:10.1002/ctd2.20
Source: Clinical Prostate Cancer - April 25, 2022 Category: Cancer & Oncology Authors: Buhai Wang Jiangquan Yu Yichun Zeng Xian Zhang Chongxu Han Qili Lu Xiaolin Wang Yichen Liang Juan J Gu Yusheng Shu Source Type: research

Recognizing the True Value of Testosterone Therapy in Health Care
Androg Clin Res Ther. 2022 Dec 28;3(1):217-223. doi: 10.1089/andro.2022.0021. eCollection 2022.ABSTRACTThere has been little recognition within the medical community of the health impact of testosterone (T) deficiency (TD), also known as hypogonadism, and the substantial benefits of testosterone therapy (TTh) on health and quality of life despite high-level clinical evidence. In a roundtable symposium, investigators summarized the contemporary evidence in several key clinical areas. TD negatively impacts human health and quality of life and is associated with increased mortality. Several studies have demonstrated that TTh ...
Source: Clinical Prostate Cancer - January 16, 2023 Category: Cancer & Oncology Authors: Abraham Morgentaler Abdulmaged Traish Rajat S Barua Paresh Dandona Sandeep Dhindsa Mohit Khera Farid Saad Source Type: research

Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news